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Abstract: The Toll-like family of immune receptors (TLRs) are critical for an efficient immune response to a variety of 
microorganisms and other antigens that may cause pathology. Modulating immune responses by targeting TLRs therefore 
has substantial therapeutic potential, and a number of TLR-based therapeutic strategies have been developed. Minimizing 
the adverse effects that may result from the therapeutic manipulation of these signalling receptors nevertheless remains a 
major challenge. Efficient responses via TLRs require the activity of the co-receptor CD14, which enhances TLR re-
sponses. In an attempt to boost the immune response for therapeutic purposes, we have sought to target CD14 to achieve 
TLR modulation. Here we discuss the design, activity and therapeutic development options of TLR-derived peptides that 
interact with CD14 and enhance its co-receptor activity, thus amplifying TLR-mediated responses. This strategy repre-
sents a promising alternative to current TLR-based therapies, as it has the potential to amplify responses to different 
pathogens mediated by different TLRs by targeting the common TLR co-receptor, CD14. 
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1. INTRODUCTION 
 Enhancing the immune response has vast therapeutic 
potential, not only for the treatment of immune deficiencies, 
but also for the development of more efficient vaccines, and 
the treatment of allergies and cancer. In this context, Toll-
like receptors (TLRs) are considered major therapeutic tar-
gets, as they play a pivotal role in the body’s immune re-
sponse. TLRs are type I transmembrane proteins expressed 
primarily on immune competent cells and also in a variety of 
other cell types. They detect microbial pathogens and trigger 
pro-inflammatory host defence responses that ultimately 
clear infections [1, 2]. TLRs also orchestrate adaptive immu-
nity, resulting in efficient responses to viruses, bacteria, 
parasites, tumours and allergens. Dysregulation of TLR re-
sponses may cause pathology. Excessive TLR-mediated re-
sponses to microbial pathogens and other antigens can lead 
to pathological inflammation (e.g. septic shock, arthritis, 
asthma and autoimmunity). By contrast, TLR hyporespon-
siveness may result in susceptibility to, and failure to clear, 
infections (e.g. sepsis-induced immunosuppression). TLR 
dysregulation may also affect the quality and/or magnitude 
of adaptive immune responses, because TLR activation pro-
motes maturation of antigen-presenting cells (APCs) such as 
dendritic cells (DCs) into fully competent APCs, guiding T 
cell differentiation toward CD4+ T-helper 1 (TH1) cells or 
CD8+ cytotoxic lymphocytes [3-6].  
 An efficient response to a variety of microbial compo-
nents and other antigens by most TLRs requires the activity 
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of the TLR co-receptor CD14. This co-receptor amplifies 
TLR-mediated pro-inflammatory and immunomodulatory 
responses [7-10]. CD14 is expressed at the cell surface 
(mainly monocytes, macrophages and neutrophils) and as a 
soluble co-receptor (sCD14) in plasma and other biological 
fluids [11, 12]. Co-receptor activity requires interaction of 
CD14 with the TLR, because CD14 is believed to deliver the 
microbial component to the TLR for optimal recognition 
[13]. 
 A number of therapeutic strategies are being developed 
that use TLR agonists as vaccine adjuvants or monothera-
peutics, or use TLR antagonists to reduce pro-inflammatory 
responses [3, 4, 14]. However, achieving optimal clinical 
benefits, while minimizing the adverse effects that may re-
sult from the therapeutic manipulation of these potent signal-
ling receptors, remains a major challenge. Here, we discuss a 
promising alternative to current TLR-based therapeutic 
strategies to boost the immune response that is based on our 
recent work aimed at amplifying the co-receptor activity of 
CD14 [15]. 
2. THERAPEUTIC RATIONALE AND CLINICAL 
DEVELOPMENT OPTIONS 
2.1. Therapeutic Rationale of the CD14-Targeting  
Strategy 
 We have sought to target the TLR co-receptor CD14 for 
therapeutic purposes. We hypothesized that by targeting 
CD14 and increasing its co-receptor capacity, the immune 
response can be boosted. This approach raises the possibility 
of amplifying immune responses to pathogens and other an-
tigens irrespective of their nature and of the TLR(s) involved 
in their recognition, because the target for modulation is the 
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common TLR co-receptor, CD14. Furthermore, this strategy 
does not require direct manipulation of the TLRs or their 
signalling pathways. 
2.2. Clinical Development Options 
2.2.1. Sepsis 
 A promising and immediate application of the CD14-
targeting strategy currently being evaluated in our laboratory 
is for the treatment of sepsis-induced immunosuppression, 
the later phase of sepsis with the highest mortality rate. Sep-
sis is a life-threatening clinical condition characterized by a 
widespread and harmful inflammation resulting from the 
immune system’s overreaction to severe infection. It can lead 
to organ dysfunction and failure, resulting in admission to an 
intensive care unit (ICU). Sepsis is a major healthcare prob-
lem, killing over 37,000 people a year in the UK alone – 
more than lung cancer or bowel, breast and prostate cancer 
combined. In the USA, sepsis is the 10th leading cause of 
death, killing over 200,000 people annually. It constitutes a 
substantial social and financial burden to healthcare systems 
worldwide, and is increasing in incidence [16]. Sepsis pa-
tients typically exhibit a biphasic immune response to infec-
tions. Survivors of an initial hyper-immune state, character-
ized by widespread inflammatory tissue injury, manifest a 
state of immune hyporesponsiveness, which includes anti-
inflammatory responses and TLR hyporesponsiveness to 
pathogens. These patients are unable to mount an appropriate 
pro-inflammatory response to clear infecting organisms, and 
are very susceptible to subsequent infections by opportunis-
tic pathogens [6, 17]. These so-called ‘second-hit’ infections 
(e.g. nosocomial infections), have a high mortality rate and, 
even when not fatal, result in numerous adverse outcomes 
including prolonged periods of costly organ support (e.g. 
mechanical ventilation) in ICUs. Thanks to improvements in 
patient management, the majority of sepsis mortality is no 
longer due to immune overreaction during the acute phase of 
the illness, but instead due to immunosuppression. The im-
munosuppression stage represents a more promising avenue 
of investigation for an immunomodulatory therapy than the 
initial hyper-immune phase, which is usually well estab-
lished before a therapeutic window presents itself. For this 
reason, and given the failure of numerous strategies aimed at 
attenuating the initial “cytokine storm”, therapies aimed at 
enhancing immune responsiveness during the immunosup-
pression phase of the illness are now being evaluated [17, 
18]. The CD14-based therapeutic strategy proposed here 
could prove to be a valuable adjunct to standard antibiotic 
therapies. It would restore the premorbid responsiveness of 
immune cells to microorganisms, thus reducing patients’ 
susceptibility to secondary infections. Correct timing for 
interventions is critical for the use of immunostimulatory 
therapies in these patients, as both pro- and anti-inflammatory 
responses do not necessarily represent subsequent events but 
might, at least in part, occur concomitantly [17, 19]. The 
extent of the pro- and anti-inflammatory responses depends 
on many factors, including pathogen virulence, bacterial 
load, host genetic factors, age and comorbidities [17]. Thus, 
patient stratification through the identification of those in the 
immunosuppression phase, for example, using immune 
status biomarkers (e.g. HLA-DR, IL-10 levels) and/or ge-
netic screening will be of paramount importance for the 
timely use of immunity-boosting approaches. 
2.2.2. Vaccine Development 
 The therapeutic potential of the proposed CD14-targeting 
strategy is not limited to the treatment of sepsis. Given the 
ability of TLRs to promote maturation of DCs into fully 
competent APCs, TLR agonists are being exploited and 
evaluated as vaccine adjuvants for infectious diseases, aller-
gies and cancer. By inducing APC maturation, TLR agonists 
help to improve the presentation of pathogen-, allergen- or 
tumour-derived antigens, leading to more efficient and spe-
cific adaptive and innate immune responses [3, 4, 20]. Ef-
forts are underway to design/discover new TLR agonists 
with increased efficacy, in order to reduce adjuvant and/or 
antigen concentration and thus lower possible vaccine toxic-
ity and cost. In this context, using a CD14-enhancing mole-
cule as co-adjuvant to amplify TLR activation would in-
crease the potency of the vaccine, allowing for a reduction in 
the dose of antigen and/or adjuvant used. Our recently re-
ported work [15] and current studies summarised below 
(secn. 3.1.) support this claim. 
2.2.3. Improved Monotherapies 
 In addition to their use as vaccine adjuvants, TLR ago-
nists are also being evaluated as monotherapeutics [3, 4]. 
Agonists for TLR3 and TLR7-TLR9 show significant prom-
ise for the treatment of cancer as well as infectious diseases, 
especially viral infections (e.g. imiquimod/TLR7 agonist, 
basal cell carcinoma and human papilloma virus infection; 
polyI:C/TLR3 agonist, TLR3+ breast carcinoma cells; CpG-
oligodeoxynucleotides/TLR9 agonist, TLR9+ chronic lym-
phocytic leukemia cells and hepatitis C). The CD14-
targeting molecules could improve the efficacy of TLR-
based monotherapeutics by amplifying TLR activation and 
helping to reduce the agonist’s dose and toxicity. CD14-
boosting molecules could also serve as valuable adjuncts to 
existing therapies for other pathologies in which amplifying 
TLR activity may be beneficial. For example, we are cur-
rently testing whether accelerating infection resolution by 
amplifying CD14’s activity, as we reported, could lower the 
extent or frequency of peritonitis episodes in peritoneal di-
alysis patients, improving dialysis efficiency. 
3. POTENTIAL THERAPEUTIC TOOLS: CURRENT 
AND FUTURE DEVELOPMENTS 
3.1. CD14-Targeting TLR Stimulatory Peptides 
 By screening a library of peptides representing the 
leucine-rich repeats (LRR) of the human TLR2 extracellular 
domain (known to be involved in molecular recognition) and 
conducting site-directed mutagenesis analysis, we have iden-
tified LRR 5, 9, 15 and 20 as those involved in the interac-
tion with the co-receptor CD14 [15]. Peptides corresponding 
to LRRs 5, 9, 15 and 20 showed an immunostimulatory ef-
fect. The most potent of them, peptides 5, 9 and 15 (corre-
sponding to TLR2 LRRs 5, 9 and 15), strongly enhanced 
neutrophil and monocyte chemoattractant (chemokine) re-
lease by leukocytes in response to TLR ligands or whole 
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bacteria. Consequently, the peptides increased phagocyte 
recruitment to the peritoneum of the infected mice, and ac-
celerated bacterial clearance in mouse models of Gram-
positive (Staphylococcus epidermidis) and Gram-negative 
(Escherichia coli) bacterial peritonitis [15]. Mechanistically, 
TLR2-derived peptides specifically interacted with CD14 
and accelerated microbial ligand transfer from CD14 to the 
TLR, resulting in increased and sustained ligand occupancy 
of TLR. This led to increased TLR clustering for signaling, 
and thus an amplified response to microbial components 
(Fig. 1). Of note, the peptides showed no activating capacity 
per se [15]. 
 Notably, the TLR2-derived peptides 5 and 9 were shown 
to rescue pro-inflammatory responses of sepsis-induced im-
munosuppressed patients ex vivo [15]. We found that whole 
blood from patients with severe sepsis, tested immediately 
after admission to ICUs, was profoundly immunosuppressed. 
This was indicated by the reduced release of neutrophil and 
monocyte chemo attractants in response to stimulation with 
TLR agonists when compared with blood from normal do-
nors. However, in the presence of TLR2 peptide 5 or 9, 
chemo attractant release by the stimulated blood from pa-
tients substantially increased. The degree of enhancement of 
the patients’ response depended on the inflammatory media-
tor, the microbial component and the patient tested. 
 Up-modulating the activity of CD14 with TLR2-derived 
peptides also affected adaptive immune responses [15]. DC 
maturation following treatment with lipopeptide or Myco-
bacterium-derived purified protein derivative (PPD) was 
enhanced in the presence of peptide 9, as indicated by the 
increased expression of major histocompatibility complex 
class II, CD83 and CD86. Consistent with its positive effect 
on DC maturation, peptide 9 also markedly enhanced inter-
leukin-2 (IL-2) production by PPD-stimulated peripheral 
blood mononuclear cells, indicating T cell activation and 
expansion [15]. Modulating CD14 activity also affected the 
cytokine profile of DCs upon stimulation [15]. DC activation 
by a typical microbial product, lipopolysaccharide (LPS), in 
the presence of peptide 9 resulted in a significant and prefer-
ential increase in the release of IL-12 and interferon-γ (IFN-
γ), which are crucial mediators of CD4+ TH1 T cell differen-
tiation and expansion. Overall, modulating the activity of 
CD14 demonstrated clear potential to affect the extent and 
quality of the adaptive immune response and favour a strong 
TH1 T cell response.  
 Thus, increasing CD14’s co-receptor activity could be 
exploited for the development of better vaccine adjuvants, by 
promoting efficient antigen presentation and T cell expan-
sion. Recent unpublished work from our laboratory supports 
this possibility. Immunisation of mice with the model antigen 
 
Fig. (1). Schematic diagram illustrating the CD14-targeting strategy to boost TLR activity. TLR2-derived peptides increase CD14’s co-
receptor activity, and thus enhance TLR responses, by specifically binding to CD14 and accelerating ligand transfer from CD14 to the TLR. 
This results in increased and sustained ligand occupancy of TLR, increased receptor clustering for signaling, and thus an amplified response. 
Toll-like receptor
CD14
Enhanced signalling
Microbial ligand
TLR2 peptide
IN
OUT
Nucleus
Increased induction of pro-inflammatory
and immunomodulatory mediators
Therapeutic Boosting of the Immune Response Current Pharmaceutical Biotechnology, 2016, Vol. 17, No. 5    417 
ovalbumin (OVA) resulted in the production of both anti-
OVA-specific plasma immunoglobulins (Igs) IgG1 and 
IgG2a. Anti-OVA IgG levels increased only slightly (not 
significantly; IgG1: ~25%, IgG2a: ~17%) when the mice 
were immunised with OVA in the presence of the TLR2 
ligand Pam3-Cys-Ser-Lys4 (Pam3Cys) lipopeptide, used as 
adjuvant. However, immunization with OVA in combination 
with Pam3Cys and the TLR2 peptide 5 resulted in a signifi-
cantly increased production of both anti-OVA IgG1 and 
IgG2a, when compared with OVA+Pam3Cys or OVA alone, 
with predominance of IgG2a (68% increase vs. OVA+ 
Pam3Cys) over IgG1 (37% increase vs. OVA+ Pam3Cys). Of 
note, administration of peptide 5 in combination with OVA 
in the absence of the adjuvant Pam3Cys did not affect the 
levels of anti-OVA Igs. This supports the concept that the 
TLR2 peptides have no activating capacity per se, as we 
previously reported [15]. Increasing the dose of OVA anti-
gen resulted in significantly higher plasma levels of anti-
OVA Igs, both in the absence and presence of the adjuvant 
Pam3Cys. Notably, when peptide 5 was administered to-
gether with Pam3Cys and the lower dose of OVA, the pro-
duction of anti-OVA Igs was increased to levels similar to 
those obtained with the higher dose of antigen in the absence 
of peptide. This highlighted the ability of the TLR2-derived 
peptide to promote a more efficient antigen presentation. 
These findings support the potential use of a CD14-boosting 
molecule as co-adjuvant, increasing the potency of vaccines 
through better antigen presentation, while reducing adjuvant 
and/or antigen concentration. This would lower the possibil-
ity of toxicity and may be particularly useful in the case of 
vaccine antigens difficult and/or expensive to synthesise. 
3.2. Development of Peptide Mimicking Small Molecules 
 The practicality of a therapeutic strategy based on the use 
of peptides, like the one described here, is supported by the 
well-documented advantages of biologics (peptides and pro-
teins) over small molecules. Biologics have much higher 
target specificity due to their large size, exhibiting much 
stronger interactions, and thus less promiscuity and side ef-
fects in drug targeting, than small-molecules [21]. The iden-
tification and development of small molecules capable of 
mimicking the effect of the peptides, however, merits to be 
attempted. Small molecule drugs offer better metabolic sta-
bility, membrane permeability, solubility and lower produc-
tion cost. To identify candidate molecules, two approaches to 
screen small chemical compound libraries are being evalu-
ated in our laboratory: in silico (virtual) screening and the 
use of encoded library technology. Selected molecules 
should bind to CD14 and increase its co-receptor capacity. 
Cell-based functional assays will then be conducted to select 
the molecule(s) with optimal co-receptor enhancing capacity.  
CONCLUSION 
 Here we have discussed the therapeutic potential of a 
strategy to boost the immune response that is based on the 
capacity of the co-receptor CD14 to amplify the response of 
a family of receptors that plays a pivotal role in the immune 
system, the TLRs. Targeting CD14 with TLR-derived pep-
tides demonstrated the ability to enhance TLR activity and 
thus the immune response to pathogens and other antigens. 
Given that CD14 works in concert with most TLRs, modu-
lating its co-receptor activity would be potentially useful as a 
therapeutic approach against a variety pathological condi-
tions in which different TLRs may be involved, e.g. infec-
tions, allergies and cancer. The advantage of using peptides 
versus small molecules to modulate CD14 activity merits 
further consideration. 
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